Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 471

1.

Low-Dose Abiraterone With Food: Rebutting an Editorial.

Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793018. doi: 10.1200/JCO.2018.79.3018. [Epub ahead of print] No abstract available.

PMID:
30188785
2.

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Szmulewitz RZ, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793190. doi: 10.1200/JCO.2018.79.3190. [Epub ahead of print] No abstract available.

PMID:
30188784
3.

Time Is Money: Optimizing the Scheduling of Nivolumab.

Ratain MJ, Goldstein DA.

J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045. [Epub ahead of print] No abstract available.

PMID:
30148658
4.

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.

Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR.

PLoS One. 2018 Aug 14;13(8):e0202272. doi: 10.1371/journal.pone.0202272. eCollection 2018.

5.

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Hlubocky FJ, Sachs GA, Larson ER, Nimeiri HS, Cella D, Wroblewski KE, Ratain MJ, Peppercorn JM, Daugherty CK.

J Clin Oncol. 2018 Aug 20;36(24):2483-2491. doi: 10.1200/JCO.2017.73.3592. Epub 2018 Jul 9.

6.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

PMID:
29948021
7.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Jun 5. doi: 10.1158/1078-0432.CCR-17-1523. [Epub ahead of print]

PMID:
29871907
8.

Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH.

Cancer. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9.

PMID:
29742281
9.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
10.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

11.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
12.

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H.

Eur Urol Focus. 2018 Feb 1. pii: S2405-4569(18)30007-5. doi: 10.1016/j.euf.2018.01.006. [Epub ahead of print]

13.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

PMID:
29385237
14.

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Chatelut E, Bruno R, Ratain MJ.

Clin Pharmacol Ther. 2018 Jun;103(6):956-958. doi: 10.1002/cpt.937. Epub 2017 Dec 1.

PMID:
29194586
15.

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.

House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ.

Xenobiotica. 2018 Oct;48(10):973-983. doi: 10.1080/00498254.2017.1386335. Epub 2017 Nov 10.

PMID:
29050522
16.

Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.

Danahey K, Borden BA, Furner B, Yukman P, Hussain S, Saner D, Volchenboum SL, Ratain MJ, O'Donnell PH.

J Biomed Inform. 2017 Nov;75:110-121. doi: 10.1016/j.jbi.2017.09.012. Epub 2017 Sep 28.

PMID:
28963061
17.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

18.

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2017 Nov;102(5):859-869. doi: 10.1002/cpt.709. Epub 2017 Jun 15.

PMID:
28398598
19.

Burdensome Research Procedures in Trials: Why Less Is More.

Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw315.

20.

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.

Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O'Donnell PH.

Pharmacogenet Genomics. 2017 May;27(5):179-189. doi: 10.1097/FPC.0000000000000275.

21.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
22.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

23.

Food Effect Studies for Oncology Drug Products.

Parsad S, Ratain MJ.

Clin Pharmacol Ther. 2017 May;101(5):606-612. doi: 10.1002/cpt.610. Epub 2017 Mar 20. Review.

PMID:
28073144
24.

Obviating the Need for Serial Biopsies Through Random Assignment.

Sweis RF, Ratain MJ.

J Clin Oncol. 2017 Jan 10;35(2):260. Epub 2016 Oct 31. No abstract available.

PMID:
28056195
25.

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH.

Clin Pharmacol Ther. 2017 Jul;102(1):106-114. doi: 10.1002/cpt.586. Epub 2017 Apr 4.

26.

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M.

Nat Rev Drug Discov. 2017 Jan;16(1):1. doi: 10.1038/nrd.2016.234. Epub 2016 Nov 25. No abstract available.

27.

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL.

Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75. Epub 2016 Nov 15.

PMID:
27845419
28.

Drug-Drug Interactions With Oral Antineoplastic Agents.

Parsad S, Ratain MJ.

JAMA Oncol. 2017 Jun 1;3(6):736-738. doi: 10.1001/jamaoncol.2016.3323. No abstract available.

PMID:
27737450
29.

Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).

de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D.

Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7.

30.

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD.

Springerplus. 2016 Jun 30;5(1):947. doi: 10.1186/s40064-016-2457-1. eCollection 2016.

31.

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.

Yee SW, Momozawa Y, Kamatani Y, Tyndale RF, Weinshilboum RM, Ratain MJ, Giacomini KM, Kubo M.

Clin Pharmacol Ther. 2016 Nov;100(5):423-426. doi: 10.1002/cpt.405. Epub 2016 Jul 21.

32.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

33.

Reply to T.A. Yap et al.

Sweis RF, Ratain MJ.

J Clin Oncol. 2016 Jul 10;34(20):2432-3. doi: 10.1200/JCO.2016.67.6163. Epub 2016 May 2. No abstract available.

PMID:
27138578
34.

Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.

Ratain MJ.

Clin Adv Hematol Oncol. 2016 Feb;14(2):78-9. No abstract available.

PMID:
27057803
35.

Disease-drug database for pharmacogenomic-based prescribing.

Hussain S, Kenigsberg BB, Danahey K, Lee YM, Galecki PM, Ratain MJ, O'Donnell PH.

Clin Pharmacol Ther. 2016 Aug;100(2):179-90. doi: 10.1002/cpt.364. Epub 2016 Jun 8.

36.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML.

Clin Transl Sci. 2016 Feb;9(1):43-50. doi: 10.1111/cts.12384. Epub 2016 Jan 21.

37.

The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.

O'Donnell PH, Danahey K, Ratain MJ.

Clin Pharmacol Ther. 2016 Apr;99(4):401-4. doi: 10.1002/cpt.333. Epub 2016 Feb 15. Review.

38.

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Sweis RF, Drazer MW, Ratain MJ.

J Clin Oncol. 2016 Feb 1;34(4):369-74. doi: 10.1200/JCO.2015.63.6126. Epub 2015 Dec 14.

39.

Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.

Rudek MA, Graham RA, Ratain MJ.

J Clin Oncol. 2016 Jan 10;34(2):103-4. doi: 10.1200/JCO.2015.64.2553. Epub 2015 Nov 30. No abstract available.

40.

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ.

Clin Cancer Res. 2015 Nov 15;21(22):5057-63. doi: 10.1158/1078-0432.CCR-15-0035.

41.

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.

Sharma MR, Ratain MJ.

Clin Cancer Res. 2016 Feb 1;22(3):527-9. doi: 10.1158/1078-0432.CCR-15-2005. Epub 2015 Oct 14.

42.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

43.

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Cancer Res. 2015 Nov 15;21(22):5092-9. doi: 10.1158/1078-0432.CCR-15-0427. Epub 2015 Jul 21.

44.

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL.

J Natl Cancer Inst. 2015 Jul 9;107(10). pii: djv188. doi: 10.1093/jnci/djv188. Print 2015 Oct.

45.

In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.

House L, Ramirez J, Seminerio M, Mirkov S, Ratain MJ.

Xenobiotica. 2015;45(11):990-8. doi: 10.3109/00498254.2015.1038743. Epub 2015 Jun 8.

46.

Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

Kaufman AL, Spitz J, Jacobs M, Sorrentino M, Yuen S, Danahey K, Saner D, Klein TE, Altman RB, Ratain MJ, O'Donnell PH.

Mayo Clin Proc. 2015 Jun;90(6):716-29. doi: 10.1016/j.mayocp.2015.03.016.

47.

The impact of industry on oncology research and practice.

Moy B, Jagsi R, Gaynor RB, Ratain MJ.

Am Soc Clin Oncol Educ Book. 2015:130-7. doi: 10.14694/EdBook_AM.2015.35.130. Review.

48.

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B.

Invest New Drugs. 2015 Aug;33(4):901-10. doi: 10.1007/s10637-015-0247-1. Epub 2015 May 8.

PMID:
25947566
49.

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.

Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL.

BMC Cancer. 2015 Feb 18;15:69. doi: 10.1186/s12885-015-1075-6.

50.

Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Ramírez J, Mirkov S, House LK, Ratain MJ.

Drug Metab Dispos. 2015 Jul;43(7):928-35. doi: 10.1124/dmd.115.063271. Epub 2015 Apr 13.

Supplemental Content

Loading ...
Support Center